|
[1]
|
Mi, J., Liang, Y., Liang, J., Gong, W., Wang, S., Zhang, J., et al. (2021) The Research Progress in Immunotherapy of Tuberculosis. Frontiers in Cellular and Infection Microbiology, 11, Article ID: 763591. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Lyu, M., Lai, H., Peng, H., Luo, H., Zhou, J., Ma, W., et al. (2025) Immunotherapy for Tuberculosis: Current Strategies and Future Directions. Military Medical Research, 12, Article No. 68. [Google Scholar] [CrossRef]
|
|
[3]
|
Chandra, P., Grigsby, S.J. and Philips, J.A. (2022) Immune Evasion and Provocation by Mycobacterium tuberculosis. Nature Reviews Microbiology, 20, 750-766. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Lombardi, A., Villa, S., Castelli, V., Bandera, A. and Gori, A. (2021) T-Cell Exhaustion in Mycobacterium tuberculosis and Nontuberculous mycobacteria Infection: Pathophysiology and Therapeutic Perspectives. Microorganisms, 9, Article No. 2460. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Moguche, A.O., Musvosvi, M., Penn-Nicholson, A., Plumlee, C.R., Mearns, H., Geldenhuys, H., et al. (2017) Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host & Microbe, 21, 695-706.e5. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Lyu, M., Xu, G., Zhou, J., Reboud, J., Wang, Y., Lai, H., et al. (2024) Single‐Cell Sequencing Reveals Functional Alterations in Tuberculosis. Advanced Science, 11, e2305592. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Johnson, J.L., Ssekasanvu, E., Okwera, A., Mayanja, H., Hirsch, C.S., Nakibali, J.G., et al. (2003) Randomized Trial of Adjunctive Interleukin-2 in Adults with Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 168, 185-191. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Zhang, R., Xi, X., Wang, C., Pan, Y., Ge, C., Zhang, L., et al. (2018) Therapeutic Effects of Recombinant Human Interleukin 2 as Adjunctive Immunotherapy against Tuberculosis: A Systematic Review and Meta-Analysis. PLOS ONE, 13, e0201025. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Denis, M., Gregg, E.O. and Ghandirian, E. (1990) Cytokine Modulation of Mycobacterium tuberculosis Growth in Human Macrophages. International Journal of Immunopharmacology, 12, 721-727. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Pedral-Sampaio, D.B., Netto, E.M., Brites, C., Bandeira, A.C., Guerra, C., Barberin, M.G., et al. (2003) Use of Rhu-GM-CSF in Pulmonary Tuberculosis Patients: Results of a Randomized Clinical Trial. Brazilian Journal of Infectious Diseases, 7, 245-252. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, Y., Liu, J., Wang, Y., Xian, Q., Shao, L., Yang, Z., et al. (2012) Immunotherapy Using IL-2 and GM-CSF Is a Potential Treatment for Multidrug-Resistant Mycobacterium tuberculosis. Science China Life Sciences, 55, 800-806. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Ma, Y., Chen, H., Wang, Y., Wang, Q., Li, Y., Zhao, Y., et al. (2011) Interleukin 24 as a Novel Potential Cytokine Immunotherapy for the Treatment of Mycobacterium tuberculosis Infection. Microbes and Infection, 13, 1099-1110. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kim, S.H., Han, S.Y., Azam, T., Yoon, D.Y. and Dinarello, C.A. (2005) Interleukin-32a Cytokine and Inducer of TNFα. Immunity, 22, 131-142. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Netea, M.G., Azam, T., Lewis, E.C., Joosten, L.A.B., Wang, M., Langenberg, D., et al. (2008) Mycobacterium tuberculosis Induces Interleukin-32 Production through a Caspase-1/IL-18/Interferon-γ-Dependent Mechanism. PLOS Medicine, 3, e277. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Li, W., Deng, W. and Xie, J. (2018) The Biology and Role of Interleukin-32 in Tuberculosis. Journal of Immunology Research, 2018, Article ID: 1535194. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Bai, X., Kim, S., Azam, T., McGibney, M.T., Huang, H., Dinarello, C.A., et al. (2010) IL-32 Is a Host Protective Cytokine against Mycobacterium tuberculosis in Differentiated THP-1 Human Macrophages. The Journal of Immunology, 184, 3830-3840. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Rodríguez, A., Tjärnlund, A., Ivanji, J., Singh, M., García, I., Williams, A., et al. (2005) Role of IgA in the Defense against Respiratory Infections. Vaccine, 23, 2565-2572. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
de L. Costello, A.M., Kumar, A., Narayan, V., Akbar, M.S., Ahmed, S., Abou-Zeid, C., et al. (1992) Does Antibody to Mycobacterial Antigens, Including Lipoarabinomannan, Limit Dissemination in Childhood Tuberculosis? Transactions of the Royal Society of Tropical Medicine and Hygiene, 86, 686-692. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Shin, A., Lee, K., Lee, J., Kim, S., Song, C., Jung, S., et al. (2006) Mycobacterium tuberculosis HBHA Protein Reacts Strongly with the Serum Immunoglobulin M of Tuberculosis Patients. Clinical and Vaccine Immunology, 13, 869-875. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Liang, L., Liu, K., Xue, Y., Chen, J., Wang, Q., Zhang, T., et al. (2018) Antibody against Ag85A Antigen of Mycobacterium tuberculosis Correlates with Protection Against Active Tuberculosis. The Journal of Infectious Diseases, 218, 598-607.
|
|
[21]
|
Williams, A., Reljic, R., Naylor, I., Clark, S.O., Falero‐Diaz, G., Singh, M., et al. (2004) Passive Protection with Immunoglobulin a Antibodies against Tuberculous Early Infection of the Lungs. Immunology, 111, 328-333. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Alvarez, N., Otero, O., Camacho, F., Borrero, R., Tirado, Y., Puig, A., et al. (2013) Passive Administration of Purified Secretory IgA from Human Colostrum Induces Protection against Mycobacterium tuberculosis in a Murine Model of Progressive Pulmonary Infection. BMC Immunology, 14, S3. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Pethe, K., Alonso, S., Biet, F., Delogu, G., Brennan, M.J., Locht, C., et al. (2001) The Heparin-Binding Haemagglutinin of M. tuberculosis Is Required for Extrapulmonary Dissemination. Nature, 412, 190-194. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Hamasur, B., Haile, M., Pawlowski, A., Schröder, U., Källenius, G. and Svenson, S.B. (2004) A Mycobacterial Lipoarabinomannan Specific Monoclonal Antibody and Its F(ab’)2 Fragment Prolong Survival of Mice Infected with Mycobacterium tuberculosis. Clinical and Experimental Immunology, 138, 30-38. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hancock, R.E.W. and Lehrer, R. (1998) Cationic Peptides: A New Source of Antibiotics. Trends in Biotechnology, 16, 82-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Yamasaki, K. and Gallo, R.L. (2008) Antimicrobial Peptides in Human Skin Disease. European Journal of Dermatology, 18, 11-21.
|
|
[27]
|
AlMatar, M., Makky, E.A., Yakıcı, G., Var, I., Kayar, B. and Köksal, F. (2018) Antimicrobial Peptides as an Alternative to Anti-Tuberculosis Drugs. Pharmacological Research, 128, 288-305. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Fehlbaum, P., Rao, M., Zasloff, M. and Anderson, G.M. (2000) An Essential Amino Acid Induces Epithelial Β-Defensin Expression. Proceedings of the National Academy of Sciences, 97, 12723-12728. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Sharma, A., Vaghasiya, K., Gupta, P., Gupta, U.D. and Verma, R.K. (2018) Reclaiming Hijacked Phagosomes: Hybrid Nano-in-Micro Encapsulated MIAP Peptide Ensures Host Directed Therapy by Specifically Augmenting Phagosome-Maturation and Apoptosis in TB Infected Macrophage Cells. International Journal of Pharmaceutics, 536, 50-62. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Rivas-Santiago, B., Castañeda-Delgado, J.E., Rivas Santiago, C.E., Waldbrook, M., González-Curiel, I., León-Contreras, J.C., et al. (2013) Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models. PLOS ONE, 8, e59119. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Rivas-Santiago, B., Rivas-Santiago, C., Sada, E. and Hernández-Pando, R. (2015) Prophylactic Potential of Defensins and L-Isoleucine in Tuberculosis Household Contacts: An Experimental Model. Immunotherapy, 7, 207-213. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Silva, J.P., Gonçalves, C., Costa, C., Sousa, J., Silva-Gomes, R., Castro, A.G., et al. (2016) Delivery of LLKKK18 Loaded into Self-Assembling Hyaluronic Acid Nanogel for Tuberculosis Treatment. Journal of Controlled Release, 235, 112-124. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Yuan, X., Wen, Q., Ni, M. and Wang, L. (2016) Immune Formulation-Assisted Conventional Therapy on Anti-Infective Effectiveness of Multidrug-Resistant Mycobacterium tuberculosis Infection Mice. Asian Pacific Journal of Tropical Medicine, 9, 293-297. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Wu, B.H., Cao, Y.S. and Chen, B.Z. (2018) Observation of Thymosin Combined with Antituberculosis Drugs for Re-treatment of Smear Positive Pulmonary Tuberculosis. Journal of Modern Clinical Medicine, 44, 58-59. (In Chinese)
|
|
[35]
|
Buccheri, S., Reljic, R., Caccamo, N., Ivanyi, J., Singh, M., Salerno, A., et al. (2007) IL‐4 Depletion Enhances Host Resistance and Passive Iga Protection against Tuberculosis Infection in BALB/c Mice. European Journal of Immunology, 37, 729-737. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Beamer, G.L., Flaherty, D.K., Assogba, B.D., Stromberg, P., Gonzalez-Juarrero, M., de Waal Malefyt, R., et al. (2008) Interleukin-10 Promotes Mycobacterium tuberculosis Disease Progression in CBA/J Mice. The Journal of Immunology, 181, 5545-5550. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Segueni, N., Tritto, E., Bourigault, M., Rose, S., Erard, F., Le Bert, M., et al. (2016) Controlled Mycobacterium tuberculosis Infection in Mice under Treatment with Anti-Il-17a or IL-17F Antibodies, in Contrast to TNFα Neutralization. Scientific Reports, 6, Article No. 36923. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Gong, W., Liang, Y., Ling, Y., Zhang, J., Yang, Y., Wang, L., et al. (2020) Effects of Mycobacterium vaccae Vaccine in a Mouse Model of Tuberculosis: Protective Action and Differentially Expressed Genes. Military Medical Research, 7, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Das, S., Chowdhury, B.P., Goswami, A., Parveen, S., Jawed, J., Pal, N., et al. (2016) Mycobacterium indicus pranii (MIP) Mediated Host Protective Intracellular Mechanisms against Tuberculosis Infection: Involvement of TLR-4 Mediated Signaling. Tuberculosis, 101, 201-209. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Sharma, S.K., Katoch, K., Sarin, R., Balambal, R., Kumar Jain, N., Patel, N., et al. (2017) Efficacy and Safety of Mycobacterium indicus pranii as an Adjunct Therapy in Category II Pulmonary Tuberculosis in a Randomized Trial. Scientific Reports, 7, Article No. 3354. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Mayosi, B.M., Ntsekhe, M., Bosch, J., Pandie, S., Jung, H., Gumedze, F., et al. (2014) Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis. New England Journal of Medicine, 371, 1121-1130. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
von Reyn, C.F., Lahey, T., Arbeit, R.D., Landry, B., Kailani, L., Adams, L.V., et al. (2017) Safety and Immunogenicity of an Inactivated Whole Cell Tuberculosis Vaccine Booster in Adults Primed with BCG: A Randomized, Controlled Trial of Dar-901. PLOS ONE, 12, e0175215. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Gong, W., Liang, Y. and Wu, X. (2018) The Current Status, Challenges, and Future Developments of New Tuberculosis Vaccines. Human Vaccines & Immunotherapeutics, 14, 1697-1716. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Cardona, P. (2006) RUTI: A New Chance to Shorten the Treatment of Latent Tuberculosis Infection. Tuberculosis, 86, 273-289. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Cardona, P., Amat, I., Gordillo, S., Arcos, V., Guirado, E., Díaz, J., et al. (2005) Immunotherapy with Fragmented Mycobacterium tuberculosis Cells Increases the Effectiveness of Chemotherapy against a Chronical Infection in a Murine Model of Tuberculosis. Vaccine, 23, 1393-1398. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Nell, A.S., D’lom, E., Bouic, P., Sabaté, M., Bosser, R., Picas, J., et al. (2014) Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection. PLOS ONE, 9, e89612. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Yan, S., Liu, R., Mao, M., Liu, Z., Zhang, W., Zhang, Y., et al. (2019) Therapeutic Effect of Bacillus Calmette-Guerin Polysaccharide Nucleic Acid on Mast Cell at the Transcriptional Level. PeerJ, 7, e7404. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R.J., Muyoyeta, M., Van Brakel, E., et al. (2018) Phase 2b Controlled Trial of M72/AS01e Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 379, 1621-1634. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Leroux-Roels, I., Forgus, S., De Boever, F., Clement, F., Demoitié, M., Mettens, P., et al. (2013) Improved CD4+ T Cell Responses to Mycobacterium tuberculosis in PPD-Negative Adults by M72/AS01 as Compared to the M72/AS02 and Mtb72f/as02 Tuberculosis Candidate Vaccine Formulations: A Randomized Trial. Vaccine, 31, 2196-2206. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Luabeya, A.K.K., Kagina, B.M.N., Tameris, M.D., Geldenhuys, H., Hoff, S.T., Shi, Z., et al. (2015) First-in-Human Trial of the Post-Exposure Tuberculosis Vaccine H56:IC31 in Mycobacterium tuberculosis Infected and Non-Infected Healthy Adults. Vaccine, 33, 4130-4140. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Aagaard, C., Hoang, T., Dietrich, J., Cardona, P., Izzo, A., Dolganov, G., et al. (2011) A Multistage Tuberculosis Vaccine That Confers Efficient Protection before and after Exposure. Nature Medicine, 17, 189-194. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Baldwin, S.L., Reese, V.A., Huang, P.D., Beebe, E.A., Podell, B.K., Reed, S.G., et al. (2016) Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. Clinical and Vaccine Immunology, 23, 137-147. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Bertholet, S., Ireton, G.C., Ordway, D.J., Windish, H.P., Pine, S.O., Kahn, M., et al. (2010) A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects against Multidrug-Resistant Mycobacterium tuberculosis. Science Translational Medicine, 2, 53ra74. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Baldwin, S.L., Reese, V.A., Larsen, S.E., Beebe, E., Guderian, J., Orr, M.T., et al. (2021) Prophylactic Efficacy against Mycobacterium tuberculosis Using ID93 and Lipid-Based Adjuvant Formulations in the Mouse Model. PLOS ONE, 16, e0247990. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Liang, Y., Zhang, X., Bai, X., Xiao, L., Wang, X., Zhang, J., et al. (2017) Immunogenicity and Therapeutic Effects of a Mycobacterium tuberculosis Rv2190c DNA Vaccine in Mice. BMC Immunology, 18, Article No. 11. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Liang, Y., Zhang, X., Bai, X., Yang, Y., Gong, W., Wang, T., et al. (2019) Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium tuberculosis Reactivation Mouse Model. Human Gene Therapy Methods, 30, 60-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Liang, Y., Wu, X., Zhang, J., Xiao, L., Yang, Y., Bai, X., et al. (2012) Immunogenicity and Therapeutic Effects of Ag85A/B Chimeric DNA Vaccine in Mice Infected with Mycobacterium tuberculosis. FEMS Immunology & Medical Microbiology, 66, 419-426. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Ramos-Espinosa, O., Mata-Espinosa, D., Francisco-Cruz, A., López-Torres, M.O., Hernández-Bazán, S., Barrios-Payán, J., et al. (2021) Immunotherapeutic Effect of Adenovirus Encoding Antimicrobial Peptides in Experimental Pulmonary Tuberculosis. Journal of Leukocyte Biology, 110, 951-963. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Bekele, A., Gebreselassie, N., Ashenafi, S., Kassa, E., Aseffa, G., Amogne, W., et al. (2018) Daily Adjunctive Therapy with Vitamin D3 and Phenylbutyrate Supports Clinical Recovery from Pulmonary Tuberculosis: A Randomized Controlled Trial in Ethiopia. Journal of Internal Medicine, 284, 292-306. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Wallis, R.S. and Zumla, A. (2016) Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review. Open Forum Infectious Diseases, 3, ofw151. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Butov, D., Zaitseva, S., Butova, T., Stepanenko, G., Pogorelova, O. and Zhelezniakova, N. (2016) Efficacy and Safety of Quercetin and Polyvinylpyrrolidone in Treatment of Patients with Newly Diagnosed Destructive Pulmonary Tuberculosis in Comparison with Standard Antimycobacterial Therapy. International Journal of Mycobacteriology, 5, 446-453. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Dwivedi, V.P., Bhattacharya, D., Singh, M., Bhaskar, A., Kumar, S., Fatima, S., et al. (2019) Allicin Enhances Antimicrobial Activity of Macrophages during Mycobacterium tuberculosis Infection. Journal of Ethnopharmacology, 243, Article ID: 111634. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Rao, M., Ligeiro, D. and Maeurer, M. (2019) Precision Medicine in the Clinical Management of Respiratory Tract Infections Including Multidrug-Resistant Tuberculosis: Learning from Innovations in Immuno-Oncology. Current Opinion in Pulmonary Medicine, 25, 233-241. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Erokhin, V.V., Vasil’eva, I.A., Konopliannikov, A.G., Chukanov, V.I., Tsyb, A.F., Bagdasarian, T.R., et al. (2008) Systemic Transplantation of Autologous Mesenchymal Stem Cells of the Bone Marrow in the Treatment of Patients with Multidrug-Resistant Pulmonary Tuberculosis. Problemy Tuberkuleza i Boleznei Legkikh, 10, 3-6.
|
|
[65]
|
Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., van Gemert, W., et al. (2012) Alarming Levels of Drug-Resistant Tuberculosis in Belarus: Results of a Survey in Minsk. European Respiratory Journal, 39, 1425-1431. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Skrahin, A., Ahmed, R.K., Ferrara, G., Rane, L., Poiret, T., Isaikina, Y., et al. (2014) Autologous Mesenchymal Stromal Cell Infusion as Adjunct Treatment in Patients with Multidrug and Extensively Drug-Resistant Tuberculosis: An Open-Label Phase 1 Safety Trial. The Lancet Respiratory Medicine, 2, 108-122. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Hoagland, D.T., Liu, J., Lee, R.B. and Lee, R.E. (2016) New Agents for the Treatment of Drug-Resistant Mycobacterium tuberculosis. Advanced Drug Delivery Reviews, 102, 55-72. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Vantourout, P. and Hayday, A. (2013) Six-of-the-Best: Unique Contributions of γδ T Cells to Immunology. Nature Reviews Immunology, 13, 88-100. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Chen, C.Y., Yao, S., Huang, D., Wei, H., Sicard, H., Zeng, G., et al. (2013) Phosphoantigen/IL2 Expansion and Differentiation of Vγ2Vδ2 T Cells Increase Resistance to Tuberculosis in Nonhuman Primates. PLOS Pathogens, 9, e1003501. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Liang, J., Fu, L., Li, M., Chen, Y., Wang, Y., Lin, Y., et al. (2021) Allogeneic Vγ9vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients with Multidrug-Resistant Tuberculosis. Frontiers in Immunology, 12, Article ID: 756495. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Introna, M. (2017) CIK as Therapeutic Agents against Tumors. Journal of Autoimmunity, 85, 32-44. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Xu, P., Xu, J.C., Chen, X.N., Ye, Z.J. and Wu, M.Y. (2015) Autologous Cytokine-Induced Killer (CIK) Immunotherapy in a Case of Disseminated Tuberculosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 32, 83-86.
|
|
[73]
|
Sada-Ovalle, I., Chiba, A., Gonzales, A., Brenner, M.B. and Behar, S.M. (2008) Innate Invariant NKT Cells Recognize Mycobacterium tuberculosis-infected Macrophages, Produce Interferon-γ, and Kill Intracellular Bacteria. PLOS Pathogens, 4, e1000239. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Rothchild, A.C., Jayaraman, P., Nunes-Alves, C. and Behar, S.M. (2014) iNKT Cell Production of GM-CSF Controls Mycobacterium tuberculosis. PLOS Pathogens, 10, e1003805. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Ishida, Y. (2020) PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells, 9, Article No. 1376. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000) Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. The Journal of Experimental Medicine, 192, 1027-1034. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Tousif, S., Singh, Y., Prasad, D.V.R., Sharma, P., Kaer, L.V. and Das, G. (2011) T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection. PLOS ONE, 6, e19864. [Google Scholar] [CrossRef] [PubMed]
|
|
[78]
|
Kamboj, D., Gupta, P., Basil, M.V., Mohan, A., Guleria, R., Bhatnagar, A., et al. (2020) Improved Mycobacterium tuberculosis Clearance after the Restoration of IFN‐γ+ TNF‐α+ CD4+ T Cells: Impact of PD‐1 Inhibition in Active Tuberculosis Patients. European Journal of Immunology, 50, 736-747. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Sada‐Ovalle, I., Ocaña‐Guzman, R., Pérez‐Patrigeón, S., Chávez‐Galán, L., Sierra‐Madero, J., Torre‐Bouscoulet, L., et al. (2015) Tim‐3 Blocking Rescue Macrophage and T Cell Function against Mycobacterium tuberculosis Infection in HIV+ Patients. Journal of the International AIDS Society, 18, Article No. 20078. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Jayaraman, P., Sada-Ovalle, I., Beladi, S., Anderson, A.C., Dardalhon, V., Hotta, C., et al. (2010) Tim3 Binding to Galectin-9 Stimulates Antimicrobial Immunity. Journal of Experimental Medicine, 207, 2343-2354. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Zhao, L., Cheng, S., Fan, L., Zhang, B. and Xu, S. (2021) TIM-3: An Update on Immunotherapy. International Immunopharmacology, 99, Article ID: 107933. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Dlugovitzky, D., Fiorenza, G., Farroni, M., Bogue, C., Stanford, C. and Stanford, J. (2006) Immunological Consequences of Three Doses of Heat-Killed Mycobacterium vaccae in the Immunotherapy of Tuberculosis. Respiratory Medicine, 100, 1079-1087. [Google Scholar] [CrossRef] [PubMed]
|
|
[83]
|
Mwinga, A., Nunn, A., Ngwira, B., Chintu, C., Warndorff, D., Fine, P., et al. (2002) Mycobacterium vaccae (SRL172) Immunotherapy as an Adjunct to Standard Antituberculosis Treatment in HIV-Infected Adults with Pulmonary Tuberculosis: A Randomised Placebo-Controlled Trial. The Lancet, 360, 1050-1055. [Google Scholar] [CrossRef] [PubMed]
|